News articles about Pfizer (NYSE:PFE) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfizer earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.8278878665479 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- GSK Pulls Out of $20 Billion Race for Pfizer Assets (usnews.com)
- Pfizer’s Ibrance hits the TV ad-spending top 10, joining stalwarts Humira and Lyrica (fiercepharma.com)
- Nike Inc, Micron Technology, Cisco Systems, Pfizer and more – PRE-MARKET (proactiveinvestors.co.uk)
- Pfizer’s smoke cessation med Chantix flunks study in adolescents; shares down 1% premarket (seekingalpha.com)
- GSK pulls out of race for Pfizer consumer assets (mobile.reuters.com)
Pfizer stock traded down $1.11 during trading hours on Friday, reaching $34.49. The company’s stock had a trading volume of 27,489,780 shares, compared to its average volume of 22,206,914. Pfizer has a 12 month low of $31.67 and a 12 month high of $39.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. The stock has a market capitalization of $205,314.33, a P/E ratio of 9.83, a P/E/G ratio of 1.73 and a beta of 0.91.
Pfizer announced that its board has approved a share buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.
A number of analysts have recently issued reports on the company. BMO Capital Markets set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “hold” rating in a research note on Monday, February 26th. Barclays boosted their price objective on Pfizer from $38.00 to $41.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Credit Suisse Group boosted their price objective on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 31st. Finally, Leerink Swann boosted their price objective on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a research note on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $39.40.
In other Pfizer news, insider Kirsten Lund-Jurgensen sold 9,510 shares of Pfizer stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the sale, the insider now owns 36,959 shares in the company, valued at $1,374,505.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Rady A. Johnson sold 27,323 shares of Pfizer stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $36.55, for a total value of $998,655.65. Following the completion of the sale, the executive vice president now owns 70,332 shares in the company, valued at approximately $2,570,634.60. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock worth $9,064,785 in the last 90 days. Company insiders own 0.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Pfizer (PFE) Stock Price” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3300333/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-pfizer-pfe-stock-price.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.